Lowest elastic modulus AM alloy on the market. BIC 95% in vivo. ×26 corrosion resistance. The only β-Ti AM alloy with a complete biological · chemical · mechanical validation triangle.
EU MDR 2017/745 classifies CoCrMo as CMR Category 1B (carcinogenic, mutagenic) — ban effective May 27, 2025. ZTM14N is the only validated alternative with superior properties across every dimension.
| Property | ZTM14N (ZTi-Med®) | Ti-6Al-4V (Grade 23) | CoCrMo |
|---|---|---|---|
| Elastic modulus | 14 GPa (L-PBF) | 110 GPa | 200–230 GPa |
| Stress shielding risk | Minimal — bone-compatible | High | Very high |
| Osseointegration (BIC) | 95% (in vivo, MDPI 2023) | 70–85% (literature) | 60–75% — poor |
| HCF fatigue endurance | ≥650 MPa | 430–500 MPa | 500–600 MPa |
| Corrosion resistance | ×26 vs Ti-6Al-4V (Wiley 2023) | Reference (1×) | Ion release — toxic |
| Cytotoxicity ISO 10993-5 | 96% viability — Grade 0 (GLP) | ~90% viability | 75% — below ISO limit |
| EU MDR 2017/745 status | Fully compliant | Compliant | ⛔ BANNED May 2025 |
| L-PBF processability | Native (EIGA powder — Z3DLAB) | Native | Limited |
| ASTM standard | WK84537 — 96.36% vote 2026 | ASTM F3001-14 | No AM ASTM |
Two peer-reviewed in vivo studies spanning 6 years, GLP chemical validation, and mechanical ASTM testing — all by independent institutions.
First-ever demonstration of bone integration into lattice implants additively manufactured by SLM process. Optimal cell size identified: 900 µm. Surgery May–July 2016 at ENVA. Characterized at BAM Berlin by high-resolution XCT.
BIC = 95% (peak value in AM biomaterial literature). BII <10 µm. Load-bearing sheep tibia, 8 weeks. Density 99.95%. Progression from 84% (2017) to 95% BIC demonstrates geometry optimization + material superiority.
Non-cytotoxic Grade 0. ZTM14N achieves 96% cell viability. CoCrMo tested under identical conditions: 75% viability (below ISO 10993-5 threshold). Regulatory-grade document, FDA-ready format.
Cervical stiffness 11,331 vs 32,359 N/mm (−65%). Lumbar: 34,391 vs 48,722 N/mm (−29%). Ultimate load cervical 11,365 N (4.5× physiological). First industrial L-PBF validation of spinal implant geometry in ZTM14N.
β-phase stability and Nb/Zr oxide network create a unique combination of biomechanical and corrosion properties with no equivalent in the metallic biomaterial landscape.
β→α'' martensitic transformation near body temperature. 6% elastic recovery demonstrated. 14 GPa modulus mimics cortical bone (10–30 GPa). Wolff's law preserved — no stress shielding.
Self-forming passive oxide layer combining Nb₂O₅ (biocompatible) and ZrO₂ (ceramic-grade corrosion resistance). Structurally intact in H₂O₂ (inflammatory environment). ×26 vs Ti-6Al-4V Wiley 2023.
900 µm optimal TPMS cell size. 3D interpenetration — bone grows into lattice cells. "Bone Spline Key" mechanism. BII <10 µm after 8 weeks. L-PBF surface roughness promotes initial cell attachment.
×26 polarization resistance vs Ti-6Al-4V in H₂O₂ solution (physiological inflammatory model). Nb and Zr oxides remain stable under redox stress. Eliminates metallic ion release that leads to periprosthetic osteolysis.
3D "tent" α-platelet architecture (Xu et al., Materials & Design 2021). Crack deflection + bifurcation. ≥600 MPa endurance (MIM) · 650 MPa (L-PBF) · both exceeding Ti-6Al-4V 430 MPa. Impurity-tolerant.
Reduced stiffness (−65% cervical) enables proper load transfer to adjacent vertebrae. Reduces stress shielding in fusion applications. Promotes biological fusion through mechano-stimulation of vertebral bone.
Ti-19Nb-14Zr pre-alloyed powder produced via EIGA process. 15–45 µm fraction. Cr-free, V-free. Direct input for L-PBF medical device manufacturing. Patent US 11,173,549 · EP3416769 · IN 477341.
Thermo-mechanical auto-locking dental implant. Three locking levels: mechanical (20°C) + thermo-mechanical (37°C, +30 MPa) + biological (BIC 95%). TPMS lattice architecture. Patent US 12,310,815 · EU.
Complete OPG→CNN→ISQ→TPMS→SLM pipeline. Pre-operative ISQ prediction (r=0.87, n=320, 4 centers). Multi-scale dilated CNN. Generative implant design guided by Wolff's law. USPTO Provisional filed.
Electrode Induction-melting Gas Atomization. Crucible-free — no contamination. Ti-19Nb-14Zr pre-alloyed barreaux → 15–45 µm spherical powder. >80% yield (patent filed).
Patient OPG → CNN bone quality analysis → ISQ prediction → TPMS geometry optimization. Patient-specific digital twin generated before surgery.
Laser Powder Bed Fusion. SLM/EOS machines. ZTM14N-optimized parameters. DNA-Implant® lattice geometry. 38 GPa modulus preserved. Density >99.9%.
XCT characterization. ISO 10993-5 compliance. ASTM WK84537 normative reference. CE MDR dossier pathway via GLP + in vivo + ASTM evidence package.
DNA-Implant® placed with thermo-mechanical locking. BIC 95% expected at 8 weeks. Wolff's law-compliant load transfer. No stress shielding. Validated by two in vivo publications.
Distribution partnerships, licensing agreements, and powder supply. Contact ZTi-Med® for technical documentation and clinical evidence packages.
Contact ZTi-Med® IP Licensing →